CBL 8851
Alternative Names: CBL-8851; CBL8851A82 and CBL8851B86Latest Information Update: 30 Apr 2024
At a glance
- Originator Changchun BCHT Biotechnology
- Class Antibacterials; Antitoxins; Monoclonal antibodies
- Mechanism of Action Tetanus toxin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Tetanus
Most Recent Events
- 11 Apr 2024 Preclinical trials in Tetanus (Prevention) in China (IM)
- 11 Apr 2024 Changchun BCHT Biotechnology plans a phase 0 trial for Tetanus (Prevention) (IM) in April 2024 (NCT06360250)